Compare AAOI & ARWR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | AAOI | ARWR |
|---|---|---|
| Founded | 1997 | 2003 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Semiconductors | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 14.8B | 12.4B |
| IPO Year | 2013 | 2009 |
| Metric | AAOI | ARWR |
|---|---|---|
| Price | $106.60 | $85.30 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 6 | 10 |
| Target Price | $66.80 | ★ $83.40 |
| AVG Volume (30 Days) | ★ 11.2M | 1.1M |
| Earning Date | 05-07-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 85.78 | ★ 99.80 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $16,142,321.00 |
| Revenue This Year | $119.87 | N/A |
| Revenue Next Year | $129.84 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $18.50 | $22.73 |
| 52 Week High | $233.67 | $95.49 |
| Indicator | AAOI | ARWR |
|---|---|---|
| Relative Strength Index (RSI) | 43.82 | 48.61 |
| Support Level | $82.67 | $82.70 |
| Resistance Level | $125.35 | $87.83 |
| Average True Range (ATR) | 11.96 | 2.65 |
| MACD | -2.34 | -0.40 |
| Stochastic Oscillator | 12.63 | 26.08 |
Applied Optoelectronics Inc is a provider of fiber-optic networking products, for four networking end-markets; internet data center, CATV, telecom, and FTTH. The Company designs and manufactures a wide range of optical communications products at varying levels of integration, from components, subassemblies, and modules to meet turn-key equipment. Through direct sales personnel, and manufacturing teams in the United States, China, and Taiwan, the company coordinates with customers to determine product design, qualifications, and performance. The Company has manufacturing and research and development facilities located in the U.S., Taiwan, and China.
Arrowhead Pharmaceuticals Inc is a commercial-stage pharmaceutical company. It is focused on the development of medicines for diseases associated with genetic abnormalities or protein overproduction. The company develops potential RNAi therapies designed to inhibit the expression of genes known to trigger diseases. Its portfolio includes potential drugs targeting Cardiometabolic, Neuromuscular, Pulmonary, Liver, and other diseases. The company also develops RNAi products and clinical candidates designed to target different cell types within the body.